Clinical Trial Update: A Study of Tanespimycin (KOS-953) in Patients With Relapsed-refractory Multiple Myeloma [Phase 2, Phase 3]

View source ↗

Summary

Clinical Trial Update reporting on a Phase 2/Phase 3 study of Tanespimycin (KOS-953) in relapsed-refractory multiple myeloma, with the trial status listed as co…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• tanespimycin (17-N-allylamino-17-demethoxygeldanamycin)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Multiple Myeloma | Phase 2, Phase 3 | Status: COMPLETED